NETCast

Dr. Gaby Gabriel, Associate Professor of Radiology and Surgery at U. of Kentucky, and member, NANETS Communications Committee, is our guest moderator for this commonly encountered management decision in NETs. He is joined by a distinguished panel of guest discussants: Dr. Callisia Clarke, Surgical Oncology, Medical College of Wisconsin; Dr. Nicholas Fidelman, Interventional Radiology, UCSF; and Dr. Michael Soulen, Interventional Radiology, Penn Medicine.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this NETCast episode, guest Moderator, Virginia Corbett, MD, Oncology, Mt Sinai Hospital, is joined by NANETS President, Dr. Thorvardur Halfdanarson, Medical Oncology, Mayo Clinic, and Dr. Nitya Raj, Medical Oncology, Memorial Sloan Kettering,for a lively, open forum discussion on the always interesting and sometimes controversial topic of biomarkers in NETs.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Tune in to NETCast to hear this recent discussion of an emerging topic in NET treatment, particularly PRRT.Participants include: Moderator Jaydira del Rivero, MD, Endocrine Oncology, National Cancer Institute, National Institutes of Health, and member of NANETS Board of Directors; Discussants – Aman Chauhan, MD, MedicalOncology, U. of Miami, Sylvester Cancer Center; and Hagen Kennecke, MD, M.D., MHA, FRCP, Medical Oncology and Medical Director of Gastrointestinal (GI) Oncology, Providence Cancer Institute.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of NETCast, recorded live on the final day of #NANETS2023, participants from the conference review the highlights of this year’s symposium, held in the beautiful city of Montreal, Quebec. Most importantly, find out who tried the poutine! The moderator of this episode is Jason Starr, DO, Medical Oncology, Mayo Clinic and Chair of NANETS Communications Committee. He is joined by the newly installed NANETS President, Thorvardur Halfdanarson, MD, Medical Oncology, Mayo Clinic; and Symposium Program Chairs, Bart Rose, MD, MAS, FACS, Surgical Oncology, U. of Alabama Birmingham, and Po Hien Ear, PhD, Basic/Translational Science, U. of Iowa.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of NETCast, "  When Surgery is Indicated in NETs from G1- G3," we hear from a distinguished panel of leading NET medical professionals, including Dr. Julie Hallet, Odette Cancer Centre at the Sunnybrook Health Sciences Centre, Dr. Callisia Clarke, Medical College of Wisconsin, Dr. Alexandra Gangi, Cedars Sinai Samuel Oschin Comprehensive Cancer Institute, and Dr. Aman Chauhan, University of Miami.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A conversation with Anees Chagpar, MD, MSc, MPH, MA, MBA, FRCS(C) FACS, Professor, Dept of Surgery, Yale University School of Medicine about her upcoming Presentation at the NANETS 2nd Annual Women in NETS Luncheon, Fri, Oct. 6, 2023 in Montreal: "Negotiation 101: How to Grow the Pie and Get Your Fair Share."See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of NETCast, which was taped live during NANETS' Cleveland NET Regional Educational Conference, leading NET medical experts held a discussion of Hormonal Management of NETs: Syndromes and Symptom Control, moderated by Amr Mohamed, MD, UH Seidman Cancer Center, University Hospital, and guests Lauren Fishbein, MD, PhD, University of Colorado, and Thorvardur Halfdanarson, MD, Mayo Clinic. Dr. Mohamed, who also served as Course Director for the NET Regional, is a medical oncologist at UH Hospitals Seidman Cancer Center, focusing on development of targeted therapies for patients with GI cancers, especially neuroendocrine tumors and colorectal cancer. Dr. Fishbein's research interests are to understand what causes neuroendocrine tumors to form (pheochromocytomas, paragangliomas, gastrointestinal and pancreatic neuroendocrine tumors). She is particularly interested in studying the inherited and tumor specific genetic changes that lead to tumor formation. Dr. Halfdanarson specializes in GI oncology. He is the program director for the Hematology/Oncology Fellowship Program at Mayo Clinic and is the current VP of the North American Neuroendocrine Tumor Society.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Tune in to hear our first taping of NETCast from Canada, recorded live during the NET Regional educational conference in Toronto. Our moderators are Dr. Julie Hallet and Dr. Simron Singh. Dr. Hallet is Associate Scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute, Assistant Professor, Dept. of Surgery, University of Toronto Surgical Oncologist, Sunnybrook Health Sciences Centre, Adjunct Scientist, Institute of Evaluative Clinical Sciences (ICES). As a surgeon investigator, her research focuses on health services population based research to examine processes, patterns of care, and outcomes of hepato-pancreato-biliary malignancies. In particular.Dr. Singh is a Medical Oncologist and Affiliate Scientist in the Odette Cancer Research Program at Sunnybrook Research Institute. He is also Assistant Professor at the University of Toronto. Dr. Singh's research interests include neuroendocrine carcinomas as well as population health and cancer care utilization discrepancies. He is co-head of a newly established multi-disciplinary specialized neuroendocrine clinic at Sunnybrook’s Odette Cancer Center, one of the first in the region. He is involved in numerous activities in the care of neuroendocrine cancer including the role of ki-67 as a prognostic marker, and the utilization of health care resources in the diagnosis and treatment of neuroendocrine tumour patients.Our guests are Dr. Callisia Clarke and Dr. Sten Myreheug. Dr. Clarke is Associate Professor, Medical College of Wisconsin. She specializes in Surgical Oncology with a focus on tumors of the upper gastrointestinal tract, sarcomas, melanomas and regional therapies for advanced malignancies. Her research interests are centered on personalized cancer care and targeted approaches in Pancreatic Neuroendocrine Tumors.Dr. Myreheug is Assistant Professor, Radiation Oncology, at Odette Cancer Centre, Sunnybrook Health Sciences Centre. He specializes in central nervous system malignancies, gastrointestinal and neuroendocrine malignancies. We are thrilled to add this important conversation to our NETCast series.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to NETCast! Today's episode is "Immunotherapy: Past, Present and Future Directions." Our guest moderator, Renuka Iyer, MD, Roswell Park Comprehensive Cancer Institute, Buffalo, NY, is a medical oncologist and longtime NANETS member, currently serving on its Board of Directors. Dr. Iyer is the Co-Director of Roswell Park's Liver and Pancreas Tumor Center, Section Chief for Gastrointestinal Oncology, Department of Medicine, and Vice Chair of Faculty Recruitment & Retention. She is also Professor of Medicine at Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo.sDr. Iyer's guests for the episode are Namrata (Neena) Vijayvergia, MD, medical oncologist at Fox Chase Cancer Center. Dr. Vijayvergia is Assistant Chief, Gastrointestinal Medical Oncology, Associate Professor, Department of Hematology/Oncology, and Medical Director, Medical Oncology. She is also an active member of NANETS, where she has served on several committees in leadership roles, including immediate past chair of the Diversity & Membership Committee, past member, Mentoring & Early Career Development Committee, and currently serving on the Scientific Review & Research Committee.Also joining as a guest is Sandip Patel, MD, Professor of Medical Oncology, University of California San Diego. Dr. Patel focuses on phase 1 immunotherapy trials and thoracic oncology immunotherapy trials. His research focus is on predictive biomarkers for immunotherapeutic response and generation of personalized cancer immunotherapy regimens.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The topic of today's episode of NETCast is "Beyond Somatostatin Analogs." Our guest moderator is Dr. Junaid Arshad, Assistant Professor of Medicine and faculty member of GI Medical Oncology at the University of Arizona. Dr. Arshad received his medical degree from King Edward Medical University, Lahore, Pakistan and completed his Internal Medicine Residency at St. Mary's Hospital, Waterbury, CT. Dr. Arshad is a Clinical and Translational Scientist with a focus on developing novel therapeutics for several areas of Upper GI Oncology. He is a member of NANETS' Communications Committee.Dr. Arshad is joined by two distinguished NET medical experts:Dr. Emily Bergsland is a medical oncologist at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center who specializes in gastrointestinal malignancies. She is a Professor of Medicine, Director of the UCSF Center for Neuroendocrine Tumors, and serves as Associate Director for Education for the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Bergsland leads a clinical-translational research program focused on neuroendocrine neoplasms of all grades, which includes clinical trials and collaborative studies related to biomarkers, imaging and clinical outcomes. She is past president of the North American Neuroendocrine Tumor Society, a longstanding member of the NCCN Neuroendocrine Tumor Guidelines panel, and past chair of the NET Task Force of the NCI Gastrointestinal Steering Committee.Dr. Pamela Kunz is an Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; Chief, GI Medical Oncology; Vice Chief, Diversity, Equity, and Inclusion. Prior to joining Yale, Dr. Kunz was Director of the Stanford Neuroendocrine Tumor Program, Leader of the Endocrine Oncology Research Group, and Director of the Neuroendocrine Tumor Fellowship. She is an international leader in the clinical care of patients with neuroendocrine tumors (NETs) and is advancing the field through clinical trials and translational science that are defining the next generation of therapies for patients with this rare diagnosis. Dr. Kunz is the current president of the North American Neuroendocring Tumor Society.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.